Zinc‐Based ROS Amplifiers Trigger Cancer Chemodynamic/Ion Interference Therapy Through Self‐Cascade Catalysis
Small · 2024
DOI: 10.1002/smll.202402320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Yun Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory …. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Zinc, Hydrogen Peroxide. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Nanozyme‐mediated chemodynamic therapy has emerged as a promising strategy due to its tumor specificity and controlled catalytic activity. However, the poor efficacy caused by low hydrogen peroxide (H 2 O 2 ) levels in the tumor microenvironment (TME) poses challenges. Herein, an H 2 O 2 self‐supplying nanozyme is constructed through loading peroxide‐like active platinum nanoparticles (Pt NPs) on zinc peroxide (ZnO 2 ) (denoted as ZnO 2 @Pt). ZnO 2 releases H 2 O 2 in response to the acidic TME. Pt NPs catalyze the hydroxyl radical generation from H 2 O 2 while reducing the mitigation of oxidative stress by glutathione, serving as a reactive oxygen (ROS) amplifier through self‐cascade catalysis. In addition, Zn 2+ released from ZnO 2 interferes with tumor cell energy supply and metabolism, enabling ion interference therapy to synergize with chemodynamic therapy. In vitro studies demonstrate that ZnO 2 @Pt induces cellular oxidative stress injury through enhanced ROS generation and Zn 2+ release, downregulating ATP and NAD + levels. In vivo assessment of anticancer effects showed that ZnO 2 @Pt could generate ROS at tumor sites to induce apoptosis and downregulate energy supply pathways associated with glycolysis, resulting in an 89.7% reduction in tumor cell growth. This study presents a TME‐responsive nanozyme capable of H 2 O 2 self‐supply and ion interference therapy, providing a paradigm for tumor‐specific nanozyme design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical Materials, Bionanomaterials & Translational Engineering…
ORCID-Profile: Huiyu Liu
Förderung
- National Natural Science Foundation of China
- Beijing Nova Program
- Fundamental Research Funds for the Central Universities
- Joint Project of BRC-BC (Biomedical Translational Engineering Research Center of BUCT-CJFH)
- Open Foundation of State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology
Zitieren
APA
Sun, Y., Qin, L., Yang, Y., Gao, J., Zhang, Y., Wang, H., Wu, Q., Xu, B., & Liu, H. (2024). Zinc‐Based ROS Amplifiers Trigger Cancer Chemodynamic/Ion Interference Therapy Through Self‐Cascade Catalysis. Small. https://doi.org/10.1002/smll.202402320
Vancouver
Sun Y, Qin L, Yang Y, Gao J, Zhang Y, Wang H, et al. Zinc‐Based ROS Amplifiers Trigger Cancer Chemodynamic/Ion Interference Therapy Through Self‐Cascade Catalysis. Small. 2024. doi:10.1002/smll.202402320
BibTeX
@article{Sun2024,
author = {Sun, Yun and Qin, Liting and Yang, Yuhan and Gao, Jingzhe and Zhang, Yudi and Wang, Hongyu and Wu, Qingyuan and Xu, Bolong and Liu, Huiyu},
title = {Zinc‐Based ROS Amplifiers Trigger Cancer Chemodynamic/Ion Interference Therapy Through Self‐Cascade Catalysis},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202402320}
}
EUVIMED